이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고위험 환자의 클로스트리디오이데스 디피실리 감염 재발 방지를 위한 생바이오치료제 신약 EXL01의 평가 (LIVEDIFF)

2026년 10월 19일 업데이트: Hospices Civils de Lyon

Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.

Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.

In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes.

Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical efficacy preventing recurrence of CDI in 69% to 89% of cases at 8 weeks post-treatment, with a good safety profile.

Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.

The aim of this Phase I/II trial is to assess the efficacy and safety of oral administration of EXL01, a single isolated unmodified strain of F. prausnitzii, in preventing CDI recurrence in high-risk patients at W8. The study will be conducted in 2 parts. The phase I (Part A) is planned to include 6 patients. The phase II (Part B) will include 50 patients in two arms (25 patients respectively in the placebo and EXL01 arm).

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

56

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Annecy, 프랑스
        • 아직 모집하지 않음
        • CH Annecy Genevois Service de Maladies infectieuses
        • 연락하다:
        • 수석 연구원:
          • Emilie PIET, MD
      • Clermont-Ferrand, 프랑스, 63003
        • 모병
        • Service d'hépato-gastroentérologie - CHU Estaing
        • 연락하다:
        • 수석 연구원:
          • Julien SCANZI, MD
      • Grenoble, 프랑스
        • 모병
        • CHU Grenoble Service Maladies infectieuses et tropicales
        • 연락하다:
        • 수석 연구원:
          • Salomé GALLET, MD
      • Lille, 프랑스
        • 모병
        • CHU Lille Unité des Maladies Infectieuses et tropicales
        • 연락하다:
        • 수석 연구원:
          • Sarah STABLER, MD
      • Lyon, 프랑스, 69004
        • 모병
        • Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse
        • 연락하다:
        • 수석 연구원:
          • Nicolas BENECH, MD
        • 연락하다:
      • Marseille, 프랑스
        • 모병
        • APHM La Timone Service de Maladies infectieuses
        • 연락하다:
        • 수석 연구원:
          • Nadim CASSIR, MD
      • Paris, 프랑스, 75012
        • 모병
        • Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP)
        • 연락하다:
        • 수석 연구원:
          • Paul MCLELLAN, MD
      • Saint-Etienne, 프랑스, 42100
        • 모병
        • Service d'infectiologie - Hôpital Nord / CHU Saint Etienne
        • 연락하다:
        • 수석 연구원:
          • Elisabeth BOTHELO-NEVERS, Pr
      • Toulouse, 프랑스, 31059
        • 모병
        • Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse
        • 수석 연구원:
          • Laurent ALRIC, Pr
        • 연락하다:
      • Valence, 프랑스, 26000
        • 모병
        • Service de Maladies Infectieuses - CH de Valence
        • 연락하다:
        • 수석 연구원:
          • Amélie DUREAULT, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adult patient ≥18 years of age

  • ≥3rd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in stool by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI or 2nd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in the stools by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI with at least one of the following risk factors:

    • Age ≥70 years
    • Chronic renal failure (haemodialysis or GFR<60ml/min
    • History of severe or severe-complicated CDI (excluding current episode) according to ESCMID 2021 criteria
    • ≥3 CDI in the last 12 months (including current episode)
    • CDI associated with care defined as CDI occurring during hospitalisation (<3 months)
  • On current or planned vancomycin treatment per os

  • Patient able to give free, informed and written consent

  • Enrolled in compulsory national social security scheme

Exclusion Criteria:

  • Currently participating or has participated in a study with an investigational compound or device within 3 months prior to the first dose of the study intervention.
  • Severe C. difficile infection severe (defined by the presence of a white blood cell count >15×10⁹ cells/L or a body temperature >38.5°C or >50% increase in the patient's baseline creatinine related to CDI at the time of V1) and/or complicated (defined by any of the factors attributed to current Clostridioides difficile infection (CDI): hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, intestinal perforation or any fulminant course of the disease)
  • Refractory C. difficile infection defined as lack of response to well-conducted per os vancomycin or fidaxomicin treatment with ≥3 liquid stools per day after ≥5 days of treatment
  • Cirrhosis with Child C score
  • Hospitalization in continuing care unit or intensive care unit
  • Personal history of gastrointestinal resection other than appendectomy (gastrectomy, esophagectomy, colonic or small bowel resection, short small bowel syndrome).
  • Personal history of gastrointestinal resection resulting in chronic diarrhea (>3 loose stools per day)
  • Inflammatory bowel disease
  • Proven uncontrolled celiac disease
  • Current stoma (ileostomy or colostomy) or within the last 6 months, or any other intra-abdominal surgery within the 3 months prior to treatment
  • major surgery or trauma ≤ 4 weeks before the start of treatment or, if > 4 weeks ago, with an unresolved healing process that could affect the assessment or safety of the study treatment.
  • Antibiotic therapy in progress or planned during the study for an infection other than CDI
  • Surgery scheduled during the study requiring perioperative antibiotics.
  • -Women without contraception*, pregnant or breastfeeding women
  • History of hypersensitivity to EXL01 and/or to any of its excipients (D-mannitol, sucrose, maltodextrin, L-cysteine, L-cysteine hydrochloride, magnesium stearate and hydroxypropylmethylcellulose), and/or to soy or soy-containing products.
  • History of hypersensitivity to vancomycin as mentioned in local prescribing information.
  • Personal history of fecal microbiota transplantation < 6 months
  • Persons deprived of liberty by judicial or administrative decision
  • Adults under legal protection or unable to give consent
  • Swallowing disorders making oral treatment impossible
  • Participation in another interventional study within 3 months prior to inclusion. (Patients who have entered the follow-up phase of an interventional study may participate provided that more than 3 months have elapsed since the last intervention).
  • Expected life expectancy of less than 6 months
  • Presents a known psychiatric disorder that would interfere with adequate cooperation with study requirements.
  • Regular use of illicit or recreational drugs that may interfere with the administration of the medication or the interpretation of the data
  • History of chronic diarrhea (> 3 watery stools per day for > 4 weeks) not related to gastrointestinal infection.
  • Clinically significant medical or surgical condition not mentioned in the above criteria which, in the opinion of the investigator, could interfere with the administration of study drug, the interpretation of study safety or efficacy data, or compromise the safety or well-being of the subject.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 파트 A(오픈 라벨 EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
실험적: 파트 B(EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
위약 비교기: 파트 B(위약)

Following a at least 10-days vancomycin treatment:

Oral placebo including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of Treatment-Emergent Adverse Events
기간: at Week 1, Week 2, Week 4, Week 8, Week 16

Phase I The primary endpoint is the occurrence of serious adverse events (CTCAE grade≥3) during treatment and follow-up and discontinuation of treatment due to adverse events attributed to treatment

at Week 1, Week 2, Week 4, Week 8, Week 16
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
기간: at Week 8

Phase II The primary endpoint is the proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of CDI-specific treatment.

at Week 8

2차 결과 측정

결과 측정
측정값 설명
기간
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
기간: at Week 8

Phase I Proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of specific treatment for CDI.

at Week 8
Evaluation of the safety and tolerability profile of oral EXL01
기간: at Week 2, Week 4, Week 8, Week 16

Phase II Occurrence of adverse events (CTCAE grade≥3) during treatment and follow-up, and discontinuation of treatment due to adverse events

at Week 2, Week 4, Week 8, Week 16
Number of stools per day over the past 24 hours
기간: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
기간: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
기간: at Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Number of stools per day over the past 24 hours
기간: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
기간: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
기간: at Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Assessment of patient quality of life during treatment and follow-up
기간: At Week 8 and Week 16

Phases I and II Patient quality of life at W8 and M4 measured by a validated digestive disease quality of life questionnaire (GIQLI)

At Week 8 and Week 16
Assessment of recurrence of C. difficile infection
기간: At Week 16

Phases I and II percentage of patients with recurrence of C. difficile infection at M4

At Week 16
Evaluation of the presence of EXL01 in the fecal microbiota
기간: At Week 8

Phases I and II Level of F. prausnitzii (qPCR) in stool at W8 versus W0

At Week 8
Assessment of EXL01 persistence in the intestinal microbiota
기간: At Week 0 and Week 16

Phases I and II Level of F. prausnitzii (qPCR) in stool at M4 versus W0

At Week 0 and Week 16
16S rRNA sequencing or shotgun
기간: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Gut microbiota composition at each visit

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
16S rRNA sequencing or shotgun
기간: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Gut microbiota composition at each visit

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
기간: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
기간: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of recurrences of C. difficile infection requiring hospitalization
기간: At Week 8

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at W8

At Week 8
Assessment of recurrences of C. difficile infection requiring hospitalization
기간: at Week 16

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at M4

at Week 16
Assessment of recurrences of C. difficile infection requiring surgery
기간: at Week 8

phases I and II phases I and II percentage of patients with a recurrence of C. difficile infection requiring surgery at W8

at Week 8
Assessment of recurrences of C. difficile infection requiring surgery
기간: at Week 16

phases I and II percentage of patients with recurrent C. difficile infection requiring surgery at M4

at Week 16

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Nicolas BENECH, MD, Hospices Civils de Lyon

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 5월 7일

기본 완료 (추정된)

2028년 1월 7일

연구 완료 (추정된)

2028년 1월 7일

연구 등록 날짜

최초 제출

2024년 2월 21일

QC 기준을 충족하는 최초 제출

2024년 3월 5일

처음 게시됨 (실제)

2024년 3월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 19일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 69HCL22_0980
  • 2023-506232-32-00 (기타 식별자: EU CT Number)
  • 2023 (미국 NIH 보조금/계약)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .